


RECEIVED

FEB 05 2002

TECH CENTER 1600/2900



Form PTO/SB/08A		Compl te if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/848,600
		Filing Date	May 3, 2001
		First Named Inventor	Peter Watts
		Group Art Unit	1644
		Examiner Name	Phillip Gambel
Sheet 1 of 2	Attorney Docket Number		10774-23U1 (WESZ/P14288US)

U.S. PATENT DOCUMENTS				
Exr Initials	U.S. Patent Document		Name of Inventor or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	Number	Kind Code (if known)		
PG	4,861,670		Mazuel et al.	08-29-1989
	4,847,091		Illum	07-11-1989
	4,946,870		Pertain III et al.	08-07-1990
	5,204,108		Illum	04-20-1993
	5,327,883		Williams et al.	07-12-1994
	5,422,097		Gwaltney et al.	06-06-1995
	5,482,706		Igari, et al.	01-09-1996
	5,554,388		Illum	09-10-1996
	5,589,453		Greve	12-31-1996
	5,690,954		Illum et al.	11-25-1997
	5,707,644		Illum	01-13-1998
PG	5,730,983		Wegner et al.	03-24-1998

FOREIGN PATENT DOCUMENTS						
Exr Initials	Foreign Patent Document			Name of Inventor or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ₁
	Country Code	Number	Kind Code (if known)			
PG	WO	90/05522	A1	Prisell, et al.	05-31-1990	
	WO	91/06282	A1	Danbiosyst UK Ltd.	05-16-1991	
	WO	93/06842	A1	Boehringer Ingelheim Pharm.	04-15-1993	
	WO	94/00485	A1	Miles, Inc.	01-06-1994	
	WO	94/27576	A1	Danbiosyst UK Ltd.	12-08-1994	
	EP	0 223 303	A1	N.V. Philips	05-27-1987	
	EP	0 314 863	B1	Baylor College of Medicine	05-10-1989	
	EP	0 362 531	A1	Molecular Therapeutics, Inc.	04-11-1990	
	GB	1 518 121		Pharmacia Aktiebolag	07-19-1978	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Ex Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.		T ₁
	AL-NAKIB, et al., "Suppression of Colds in Human Volunteers Challenged with Rhinovirus by a New Synthetic Drug (R61837)," <i>Antimicrobial Agents and Chemotherapy</i> 33(4):522-526 (1989).		
	DEASY, et al., "Rheological evaluation of deacetylated gellan gum (Gelrite) for pharmaceutical use," <i>International Journal of Pharmaceutics</i> , 73:117-123 (1991).		
	FLORENCE, et al., <u>Physicochemical Principles of Pharmacy</u> , (2 nd ed.), Ch. 8, pp 281-333, (MacMillan Press, 1988).		
PG	HAYDEN, et al., "Prevention of Natural Colds by Contact Prophylaxis with Intranasal Alpha ₂ -Interferon", <i>New England Journal of Medicine</i> 314(2):71-75 (1986).		

Examiner Signature	PHILLIP GAMBEL 1/2/03	Date Considered	
--------------------	-----------------------	-----------------	--

**Complete if Known**

Application Number	09/848,600
Filing Date	May 3, 2001
First Named Inventor	Peter Watts
Group Art Unit	1644
Examiner Name	Phillip Gambel
Attorney Docket Number	10774-23U1 (WESZ/P14288US)

Sheet	2	of	2
-------	---	----	---

TECH CENTER 1600/2900

FFB 05 2002

Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.
pg.	ILLUM, "The nasal delivery of peptides and proteins", <i>Trends in Biotechnology</i> 9(8):284-289 (1991).
	ILLUM, "Nasal delivery of peptides, factors affecting nasal absorption", in <u>Topics in Pharmaceutical Science</u> , Ch. 5, pp. 71-82 (1991).
	KUBLIK, et al., "Rheological Properties of Polymer Solutions as Carriers for Nasal Drug Delivery Systems," <i>European Journal of Pharmaceutics and Biopharmaceutics</i> 39(5):192-196 (1993).
	MARLIN, et al., "A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection" <i>Nature</i> 344:70-72 (1990).
	NAGAI, et al., "Application of Chitin and Chitosan to Pharmaceutical Preparations," <i>Proc. Jt. US-Jpn. Seminar Adv. Chitin, Chitosan, Relat. Enzymes</i> 21-39 (Academic Press, Orlando) (1984).
	SANZGIRI, et al., "Gellan-based systems for ophthalmic sustained delivery of methylprednisolone," <i>Journal of Controlled Release</i> 26:195-201 (1993).
	SAWAYANAGI, et al., "Dissolution Properties and Bioavailability of Phenytoin from Ground Mixtures with Chitin or Chitosan," <i>Chem. Pharm. Bull.</i> 31(6):2062-2068 (1983).
	VON ITZSTEIN, et al., "Rational design of potent sialidase-based inhibitors of influenza virus replication," <i>Nature</i> 363:418-423 (1993).
	AHERN, et al. "Chemical and Physical Pathways of Protein Degradation," <u>Pharmaceutical Biotechnology</u> , Vol. 2, Part A, <u>Stability of Protein Pharmaceuticals</u> , pp. 124-125 (Plenum Press, New York) (1992).
	BANKER, et al. <u>Modern Pharmaceutics</u> (3 rd edition), pp. 852-853 (Marcel Dekker, Inc., New York) (1996).
	LEE, <u>Peptide and Protein Drug Delivery</u> , pp. 36-37, 148-151 (Marcel Dekker, Inc., New York) (1991).
	MCNALLY, <u>Protein Formulation and Delivery</u> , pp.32-35, 40-41,130-133 (Marcel Dekker, Inc.) (2000).
pg.	FLORENCE, et al., <u>Physicochemical Principles of Pharmacy</u> , (3 rd edition), Ch. 11, pp. 504-505, (Macmillan Press, 1998).

PHILIP GAMBER 1/2/03

Date
Considered

T₁ - Place a check mark if English language translation is attached.
County Code - see Phila Doc #52886
Kind Code - see Phila Doc # 99754